Gilead Sciences will acquire CymaBay Therapeutics for $4.3 billion, adding a new treatment for a liver disease that is on track for approval later this year.
Judge David Alan Ezra in the Western District of Texas granted the Biden administration's request to dismiss the lawsuit, ruling that the plaintiffs lacked standing.
The executives from Bristol Myers Squibb, Johnson & Johnson and Merck spent almost three hours in front of the committee going back and forth about pricing practices and how the companies spend their money.